Optimized Virologic Response in Hepatitis C Virus Genotype 4 with Peginterferon-α2a and Ribavirin

Letters6 January 2004Optimized Virologic Response in Hepatitis C Virus Genotype 4 with Peginterferon-α2a and RibavirinMoises Diago, MD, Tarek Hassanein, MD, Juan Rodés, MD, Andrew M. Ackrill, PhD, and Farhad Sedarati, PhDMoises Diago, MDFrom Hospital General Universitario, Valencia, Spain; University of California, San Diego, San Diego, CA 92103 University of Barcelona, Barcelona, Spain; Products Ltd., Hertfordshire, United Kingdom; and Hoffmann-La Roche, Nutley, NJ., Tarek Hassanein, MDFrom Hospital General Universitario, Valencia, Spain; University of California, San Diego, San Diego, CA 92103 University of Barcelona, Barcelona, Spain; Products Ltd., Hertfordshire, United Kingdom; and Hoffmann-La Roche, Nutley, NJ., Juan Rodés, MDFrom Hospital General Universitario, Valencia, Spain; University of California, San Diego, San Diego, CA 92103 University of Barcelona, Barcelona, Spain; Products Ltd., Hertfordshire, United Kingdom; and Hoffmann-La Roche, Nutley, NJ., Andrew M. Ackrill, PhDFrom Hospital General Universitario, Valencia, Spain; University of California, San Diego, San Diego, CA 92103 University of Barcelona, Barcelona, Spain; Products Ltd., Hertfordshire, United Kingdom; and Hoffmann-La Roche, Nutley, NJ., and Farhad Sedarati, PhDFrom Hospital General Universitario, Valencia, Spain; University of California, San Diego, San Diego, CA 92103 University of Barcelona, Barcelona, Spain; Products Ltd., Hertfordshire, United Kingdom; and Hoffmann-La Roche, Nutley, NJ.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-140-1-200401060-00035 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Background: Infection with hepatitis C virus (HCV) genotype 4 has been termed "difficult to treat" because of poor sustained virologic response to conventional interferon (1). Monotherapy with peginterferon-α2a (40 kilodalton) (PEGASYS, Hoffmann-La Roche Ltd., Basel, Switzerland) improves sustained virologic responses (45% vs. 0% for interferon-α2a) (2).Objective: To study effects of treatment with peginterferon-α2a (40 kilodalton) and ribavirin (COPEGUS, Hoffmann-La Roche Ltd.) in patients infected with HCV genotype 4.Methods and Findings: We conducted 2 studies; both were approved by institutional review boards, and all patients gave informed consent. Patients in the first study (n = 13) were ...References1. Zylberberg H, Chaix ML, Brechot C. Infection with hepatitis C virus genotype 4 is associated with a poor response to interferon-α [Letter]. Ann Intern Med. 2000;132:845-6. [PMID: 10819720] LinkGoogle Scholar2. Sherman M, Marinos G, Sedarati F. Infection with hepatitis C virus genotype 4 is associated with a poor response to interferon-α [Letter]. Ann Intern Med. 2001;135:927-8. [PMID: 11712887] LinkGoogle Scholar3. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, et al . Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-82. [PMID: 12324553] CrossrefMedlineGoogle Scholar4. Hadziyannis SJ, Cheinquer H, Morgan T, et al . Peginterferon alfa-2a (40KD) (PEGASYS®) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining effect of duration of treatment and RBV dose. J Hepatol. 2002;36:3. CrossrefGoogle Scholar5. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al . Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet. 1998;352:1426-32. [PMID: 9807989] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Moises Diago, MD; Tarek Hassanein, MD; Juan Rodés, MD; Andrew M. Ackrill, PhD; Farhad Sedarati, PhDAffiliations: From Hospital General Universitario, Valencia, Spain; University of California, San Diego, San Diego, CA 92103 University of Barcelona, Barcelona, Spain; Products Ltd., Hertfordshire, United Kingdom; and Hoffmann-La Roche, Nutley, NJ. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoInfection with Hepatitis C Virus Genotype 4 Is Associated with a Poor Response to Interferon-α Hervé Zylberberg , M. L. Chaix , and Christian Bréchot Infection with Hepatitis C Virus Genotype 4 Is Associated with a Poor Response to Interferon-α Morris Sherman , George Marinos , and Farhad Sedarati Metrics Cited byPredictors of hepatitis C virus recurrence after living donor liver transplantation: Mansoura experienceSustained virological response and its treatment predictors in hepatitis C virus genotype 4 compared to genotypes 1, 2, and 3: a meta-analysisCurrent status and emerging challenges in the treatment of hepatitis C virus genotypes 4 to 6Meta-analysisOptimizing Outcome of Recurrent Hepatitis C Virus Genotype 4 After Living Donor Liver Transplantation: Moving Forward by Looking BackPegylated versus standard interferon plus ribavirin in chronic hepatitis C genotype 4: A systematic review and meta-analysisAdipokines and insulin resistance, predictors of response to therapy in Egyptian patients with chronic hepatitis C virus genotype 4Relationship of interferon-γ-inducible protein-10 kDa with viral response in patients with various heterogeneities of hepatitis C virus genotype-4Safety and efficacy of treatment with pegylated interferon alpha-2a with ribavirin in chronic hepatitis C genotype 4Predictors of sustained virological response in Greek and Egyptian patients with hepatitis C genotype 4: Does ethnicity matter?Hepatitis C Genotype 4 Therapy: Progress and ChallengesRecommendations for the prevention, diagnosis, and treatment of chronic hepatitis B and C in special population groups (migrants, intravenous drug users and prison inmates)Management of hepatitis C virus genotype 4: Recommendations of An International Expert PanelHepatitis C virus genotype 4 therapy: progress and challengesThe neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus reportDifferential viral kinetics in treated genotype 4 chronic hepatitis C patients according to ethnicityHepatitis C genotype 4 therapy: increasing options and improving outcomesSpotlight on Peginterferon-α-2a (40 kD) Plus Ribavirin in the Management of Chronic Hepatitis C Mono-Infection†Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4Tratamiento de la infección por el virus de la hepatitis C. Estado actual y perspectivasResultados del tratamiento con interferón pegilado y ribavirina para la hepatitis crónica por el virus C en la práctica clínica. Experiencia de 5 añosVery Early Viral Kinetics on Interferon Treatment in Chronic Hepatitis C virus Genotype 4 InfectionHepatitis C genotype 4: What we know and what we don't yet knowImproving Outcome in Patients With Hepatitis C Virus Genotype 4Clinical and Pathological Characteristics and Response to Combination Therapy of Genotype 4 Chronic Hepatitis C Patients: Experience from a Spanish CenterCurrent therapy for hepatitis CGenotypic variations around the world: Is hepatitis C virus evolving?Management and Treatment of Hepatitis C Viral Infection: Recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program OfficeTratamiento de pacientes genotipo 4Distribution of hepatitis C virus genotypes in the Middle EastIndividualisierte Behandlung der chronischen Hepatitis CChronic Hepatitis C Virus Management: 2000–2005 UpdatePegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infectionResponse to Interferon-Based Therapies in HIV-Infected Patients with Chronic Hepatitis C Due to Genotype 4Chronic Hepatitis C and Genotyping: The Clinical Significance of Determining HCV GenotypesHepatitis B and C genotyping: methodologies and implications for patient managementMeta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4Heterogeneous Virologic Response Rates to Interferon-Based Therapy in Patients with Chronic Hepatitis C: Who Responds Less Well?Stefan Zeuzem, MDAntiviral Combination Therapy for Treatment of Chronic Hepatitis B, Hepatitis C, and Human Immunodeficiency Virus Infection 6 January 2004Volume 140, Issue 1Page: 72-73KeywordsAdverse eventsBody weightDiagnostic techniquesHepatitis C virusInfectious hepatitisInstitutional review boardsInterferonsPatientsResearch laboratoriesRNA ePublished: 6 January 2004 Issue Published: 6 January 2004 Copyright & PermissionsCopyright © 2004 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...